TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01768520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteron tab. 150mg(vitis vinifera extract 150mg) : twice daily for 12 weeks
Description: 1. morning : 1 tab. of active Entelon 150mg plus 1 cap. of placebo Celebrex~2. evening : 1 tab. of active Entelon 150mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celebrex cap. (celecoxib 200mg) : once daily, for 12 weeks
Description: 1. morning : 1 tab. of placebo Entelon 150mg + 1 cap. of active Celebrex~2. evening : 1 tab. of placebo Entelon 150mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1. morning : 1 tab. of placebo Entelon 150mg + 1 cap. of placebo Celebrex~2. evening : 1 tab. of placebo Entelon 150mg
Study: NCT04697303

Intervention type: OTHER
Intervention: anorectal function test
Description: anorectal function test
Study: NCT00361348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Study: NCT02581410

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)
Description: 2 doses administered by intramuscular (IM) injection into the deltoid muscle of the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)
Description: 2 doses administered by intramuscular (IM) injection into the deltoid muscle of the non-dominant arm.
Study: NCT00658385

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GCSF, Central venous line placement, Stem cell Collection (leukapheresis)
Description: Daily injections under the skin of a GCSF. This is done for 5 to 6 days. On days 1, 3,5, and if need on day 6. To collect stem cells, we need good access to this blood. If the patient has good veins, we do this by placing an IV on each one of their arms. The peripheral blood stem cell collection is usually an outpatient procedure and takes about 3 to 4 hours. You will have blood work and a physical exam on days one, three, and five while you are getting GCSF.~These will be done again 24 hours after your stem cells are collected.
Study: NCT00759941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1% ophthalmic solution (Azopt)
Description: One drop three times a day in both eyes for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo eye drops
Description: One drop three times a day in both eyes for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% ophthalmic solution (Xalatan)
Description: One drop once a day in both eyes for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost 0.005% ophthalmic solution (Xalatan)
Description: One drop once a day in both eyes for 3 months
Study: NCT00472030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Patients will be treated with 150-375 milligrams of Omalizumab (Xolair), based on their baseline weight and serum Immunoglobulin E levels. Omalizumab will be administered subcutaneously on Day 1, and on Week 2, 4, 6, 8, 10, 12 and 14 treatment.
Study: NCT03613285

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional brackets
Description: conventional brackets with MBT prescription was used for orthodontic treatment and root resorption was assessed.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: smart clip passive self ligating brackets
Description: smart clip passive self ligating brackets with MBT prescription was used for orthodontic treatment and root resorption was assessed.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Empower active self ligating brackets
Description: Empower active self ligating brackets with MBT prescription was used for orthodontic treatment and root resorption was assessed.
Study: NCT00722852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketoprofen in Diractin®
Description: 100 mg (b.i.d.)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 mg (b.i.d.)
Study: NCT03646500

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Retrobulbar Block
Description: Anesthetic nerve block administered in the retrobulbar space prior to transcleral diode procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil administered as intravenous infusion prior to transcleral diode procedure
Study: NCT03203720

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Motivational Intervention
Description: A brief motivational intervention centered around Motivational Interviewing (MI) techniques. Sessions are adjunct to standard clinical care, and focus on psychoeducation regarding treatment for bipolar disorder, and resolving ambivalence regarding taking medications for mood disorder.
Study: NCT03035968

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vojta therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physiotherapy
Study: NCT02920333

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional rehab training
Description: Conventional rehab training will be conducted daily for 10 days, after NIBS intervention.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: conventional rehab training
Description: Conventional rehab training will be conducted daily for 10 days, after NIBS intervention.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional rehab training
Description: Conventional rehab training will be conducted daily for 10 days, after NIBS intervention.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: tDCS will be applied 10 days, followed by conventional rehab training. Stimulation will be conducted at the intensity of 2 mA and last for 20 minutes. anode will be placed over the affected primary motor cortex (M1) of cortical representation of the tibialis anterior muscle (TA), while the cathode will be used as reference electrode and placed over the forehead of the unaffected side.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: rTMS will be applied 10 days, followed by conventional rehab training. Subjects will receive 10 Hz rTMS, and a total of 1200 pulses will be delivered for one treatment session.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: The same stimulation parameters as tDCS treatment will be employed for the sham stimulation. However, the current will be applied for 30 seconds only, to give subjects the sensation of the stimulation.
Study: NCT01603186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine Fumarate Tablets 25 mg
Description: 25 mg tablet once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine Fumarate
Description: 25 mg tablet once a day
Study: NCT01947192

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Treatment with chlorhexidine
Description: Application of 2% chlorhexidine digluconate (60 seconds) after the etching procedure and before the adhesive system.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Water pre-treatment
Description: Treatment of acid etched dentin with sterilized water for 60 s before adhesive system application
Study: NCT00472030

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: Prednisone, to a maximum dose of 0.5 mg/kg/day.
Study: NCT04246567

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mean Blood Pressure (MBP)
Description: Mean blood pressure (MBP) for patients 50-65 mmHg

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mean Blood Pressure (MBP)
Description: Mean blood pressure (MBP) for patients 50-65 mmHg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Add to 0.5 mcg / kg fentanyl.
Description: When BIS values are between 40-60 and muscle relaxation was sufficient (TOF 0), a 20% increase in the initial blood pressure and heart rate values of patients were added to 0.5 mcg / kg fentanyl.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Add to 0.5 mcg / kg fentanyl.
Description: When BIS values are between 40-60 and muscle relaxation was sufficient (TOF 0), a 20% increase in the initial blood pressure and heart rate values of patients were added to 0.5 mcg / kg fentanyl.
Study: NCT02893930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapanisertib
Description: Given PO
Study: NCT03143660

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Coaching
Description: The eight weekly 30-minute Fitline calls provide personalized behavioral counseling and coaching to guide parents in improving their child's weight-related behaviors through targeted lifestyle changes recommended by the AAP for Stage 1, Prevention Plus. Calls are scheduled at a time convenient for the parent, including nights and weekends, with one nutritionist assigned to a family for consistency.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Materials
Description: The workbook contains tips and practical strategies for implementing the AAP-recommended behavior changes discussed in the counseling sessions to support families in making lifestyle changes.
Study: NCT01314820

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: normal saline injection
Description: 20 cc normal saline injection into knee joint

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham injection
Description: no saline injection
Study: NCT01137526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-384
Description: Subjects will take study drug once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-384
Description: Subjects will take study drug once daily for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: donepezil
Description: Subjects will take study drug once daily for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects will take study drug once daily for 12 weeks
Study: NCT00688831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1305
Description: Solution for iv infusion , single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NaCl solution for iv infusion, single dose
Study: NCT00001521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludrocortisone
Description: Since hydrocortisone dosage will be reduced , some patients may develop symptoms or signs of adrenal insufficiency. Patients will continue to receive an optimal fludrocortisone dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: reduced hydrocortisone dose can normalize the growth and adult stature of children with congenital adrenal hyperplasia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: reduced hydrocortisone dose can normalize the growth and adult stature of children with congenital adrenal hyperplasia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Aromatase inhibitors work by inhibiting the action of the enzyme aromatase, which converts androgens into estrogens by a process called aromatization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Aromatase inhibitors work by inhibiting the action of the enzyme aromatase, which converts androgens into estrogens by a process called aromatization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flutamide
Description: Non steroidal anti-androgen that prevents the action of androgens by blocking receptor sites in target tissue. It may also produce changes in testosterone and estradiol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flutamide
Description: Non steroidal anti-androgen that prevents the action of androgens by blocking receptor sites in target tissue. It may also produce changes in testosterone and estradiol
Study: NCT02012413

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PST - Pulsed Signal Therapy
Description: PST application is a painless over-the-skin eletromagnetic field application. 9 sessions of application of electromagnetic therapy - PST - during 60 minutes

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Sham PST
Description: Placebo PST will be performed by applying the same device over the patient knee. The machine is not applying the PST but it appears to be on. In this way, patients are blinded to the intervation.~9 sessions of application of Sham PST - during 60 minutes
Study: NCT04080505

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SSKI- Potassium Iodide
Description: 1g/mL, 2 drops orally 3 times a day for 7 days before surgery
Study: NCT00706433

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aminolevulinic acid HCL (ALA)
Description: Levulan Kerastick containing 20% aminolevulinic acid HCL (ALA). Up to 4 treatments will be given at 3 week intervals.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aminolevulinic acid HCL (ALA)
Description: Levulan Kerastick containing 20% aminolevulinic acid HCL (ALA). Up to 4 treatments will be given at 3 week intervals.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle (VEH)
Description: Levulan Kerastick containing vehicle ingredients only (VEH). Up to 4 treatments will be given at 3 week intervals.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle (VEH)
Description: Levulan Kerastick containing vehicle ingredients only (VEH). Up to 4 treatments will be given at 3 week intervals.
Study: NCT02391857

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastric decompression
Description: Insertion the Naso(Oro)-gastric tube for early gastric decompression during CPR
Study: NCT01614743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA
Description: Experimental injection given at baseline and Week 16

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bacteriostatic saline
Description: Placebo at baseline, incobotulinumtoxinA at 16 weeks
Study: NCT02853253

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SMOFlipid®
Description: SMOFlipid® (FreseniusKabi France, Sèvres, France). It is a 3rd generation LE containing a physical mixture of soybean oil (30%), MCT (30%), olive oil (25%) and fish oil (15%). Its ratio omega6/omega 3 is 2,5/1. SMOF will be initiated within the 1st day of life of neonates and will be prescribed daily by the attending physician following these guidelines: initiation rate: 1 g/kg/day; daily increase: 0.5 to 1 g/kg/day ; target: 3 to 4 g/kg/day.~All included preterms will receive nutritional support according to a single protocol based on the ESPGHAN recommendations: parenteral glucose and amino acids (Primene 10%, Clintec Parenteral, Maurepas, France) soon after birth (in their 1st day of life). Initiation rate of parenteral glucose and amino acids will be 6 to 8 g/kg/day and 2 g/kg/day respectively. The daily increase of parenteral glucose and amino acids will be 1 to 2 g/kg/day and 0.5 g/kg/day respectively, for a target rate of 14 to 17 g/kg/day and 3.5 g/kg/day respectively.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Medialipide®
Description: Medialipide® 20% (B Braun Medical, Boulogne, France). It is a second generation LE containing soybean oil (50%) and MCT (50%). Its ratio omega6/omega 3 is 7/4. Medialipide will be initiated within the 1st day of life of neonates and will be prescribed daily by the attending physician following these guidelines: initiation rate: 1 g/kg/day ; daily increase: 0.5 to 1 g/kg/day; target: 3 to 4 g/kg/day.~All included preterms will receive nutritional support according to a single protocol based on the ESPGHAN recommendations: parenteral glucose and amino acids (Primene 10%, Clintec Parenteral, Maurepas, France) soon after birth (in their 1st day of life). Initiation rate of parenteral glucose and amino acids will be 6 to 8 g/kg/day and 2 g/kg/day respectively. The daily increase of parenteral glucose and amino acids will be 1 to 2 g/kg/day and 0.5 g/kg/day respectively, for a target rate of 14 to 17 g/kg/day and 3.5 g/kg/day respectively.
Study: NCT02441712

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PENS

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: PENS
Study: NCT01510522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucophage
Description: Glucophage Powder for oral solution in sachets (metformin hydrochloride in 850mg strengths) Dosing schedule: \> 1.700mg/day for 6 month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucophage
Description: Glucophage tablets (metformin hydrochloride in 850mg strengths)~Dosing schedule: \> 1.700mg/day for 6 month
Study: NCT01259284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 1 capsule by mouth every morning 5 days before surgery, and 9 days after surgery or until discharge.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil Supplement
Description: 3 capsules by mouth in the morning and evening 5 days before surgery, and 9 days after surgery or until discharge.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo group: 4 capsules by mouth every morning and 3 every evening for 5 days before surgery and 9 days after surgery or until discharge.~Atorvastatin group: 3 capsules by mouth every morning and evening, 5 days before surgery and 9 days after surgery or until discharge.~Fish Oil Supplement group: 1 capsule by mouth every morning 5 days before surgery and 9 days after surgery or until discharge.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo group: 4 capsules by mouth every morning and 3 every evening for 5 days before surgery and 9 days after surgery or until discharge.~Atorvastatin group: 3 capsules by mouth every morning and evening, 5 days before surgery and 9 days after surgery or until discharge.~Fish Oil Supplement group: 1 capsule by mouth every morning 5 days before surgery and 9 days after surgery or until discharge.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group: 4 capsules by mouth every morning and 3 every evening for 5 days before surgery and 9 days after surgery or until discharge.~Atorvastatin group: 3 capsules by mouth every morning and evening, 5 days before surgery and 9 days after surgery or until discharge.~Fish Oil Supplement group: 1 capsule by mouth every morning 5 days before surgery and 9 days after surgery or until discharge.
Study: NCT03809741

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bundled L&D Infection Prevention Interventions
Description: The following bundle of infection prevention interventions will be implemented at each study site for 12 weeks:~Education: 2 day module of Infection Prevention and Control (IPC) training and education at the beginning of the period, with specific information pertaining to labor and delivery. A refresher course will be administered at week 6.~Feedback: Monthly feedback sessions detailing IPC practices~Reminders: Visual poster reminders on hand hygiene and daily SMS reminders on best practices for peripartum and postnatal care.~Alcohol Hand Rub (AHR) supply: Provision of AHR, produced by WHO standards and guides in collaboration with district pharmacy
Study: NCT03549312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genvoya
Description: Switching to Genvoya for 48 weeks in patients with HIV/HCV co-infection and stably suppressed HIV RNA, prior to starting HCV treatment, while receiving methadone or buprenorphine/naloxone as opioid substitution therapy.~Plasma HIV-1 RNA \< 50 copies/mL at weeks 4, 12, 24, 36 and 48.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epclusa
Description: HCV therapy with direct-acting-antiviral therapy with Epclusa in HIV-HCV co-infected patients with suppressed HIV RNA, receiving methadone as opioid substitution therapy.~Plasma HCV RNA viral load at weeks 12, 24, 36, 48, 72 and 96.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biktarvy
Description: Switching to Biktarvy for 48 weeks in patients with HIV previously treated with Genvoya, stably supressed HIV RNA, while receiving methadone or buprenorphine/naloxone as opioid substitution therapy.~Plasma HIV-1 RNA \< 50 copies/mL at weeks 52, 60, 72, 84 and 96.
Study: NCT03039257

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Vitamin A
Description: Dose administration will start with 2500 IU/kg with maximum dose of 250,000 IU orally.
Study: NCT03333837

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dance Group
Description: Active imagination refers to working with imagery and is crucial in improvisatory practice. Verbal auditory cues are used to create movement scenarios that cue or activate the motor imagination. Variability means the improvisational method does not aim to learn a specific movement pattern and habituate to it. Cues are delivered quickly, one after another. Within an average of two minutes, tasks requiring quicker decision-making are introduced. Pacing is the rate at which new movement prompts are presented. Quick changes in pace avoid defaulting to habitual responses, thereby facilitating new movement options. Participants cannot rely on copying another, memory, or anticipation to address the motor problem.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-Group Dance
Description: The caregiver will be asked to stay in the area while the subject is dancing. A video camera will be affixed in an upper corner of the room to record individual dance sessions. This recording will yield data that a trained student or staff member can view and code to document movement fidelity (e.g., that the person has responded to the dance prompts and for the purpose of comparing the amount of quality of movements that occur in individual vs. group dance settings). For the first two sessions, study staff would observe the full dance session from outside the room to be sure that instruction was clear and adherence was attained, and that no safety issues arise.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Group
Description: The social group will consist of improvisational party games to foster curiosity and playfulness, use imagery, and encourage non-judgment. Games that may be used include 'Balderdash', 'Wise and Otherwise', 'Charades', 'Pictionary', and 'Tell Me A Story' cards. These games will also use the same core strategies as the dance group. Games will be varied within an hour-long session to incorporate pacing and variability into the social group, akin to the dance group. The social group will occur 2x/week for 1 hour each time and be led by the same instructors who lead the Dance Group, to control for effects of personality of the group leader.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: No Contact
Description: The condition of not receiving an intervention can have ethical implications and reduce retention rates. Therefore, these participants will be invited to join in a weekly community improvisational dance class after they complete the study, for as many sessions as they would like.